Complex Transfusion Issues in Pediatric Hematopoietic Stem Cell Transplantation

Transfusion Medicine Reviews

Volumn 30, Issue 4, 2016, Pages 202-208

  Webb, Jennifer ^a   Abraham, Allistair ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

ABO incompatibility; Hematopoietic stem cell transplant; Pediatric; Transfusion

Indexed keywords

PROCOAGULANT; COAGULATING AGENT; SIGNAL PEPTIDE;

BLEEDING; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW TRANSPLANTATION; CYTOPENIA; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON OVERLOAD; OUTCOME ASSESSMENT; PATIENT SAFETY; PRACTICE GUIDELINE; REVIEW; SCREENING TEST; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; TREATMENT PLANNING; ALLOTRANSPLANTATION; BLOOD; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; CHILD; HEMATOLOGY; HEMATOPOIESIS; HEMOLYSIS; IMMUNOLOGY; PROCEDURES; THROMBOCYTE TRANSFUSION; TRANSPLANTATION CONDITIONING;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; CHILD; COAGULANTS; HEMATOLOGY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PLATELET TRANSFUSION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84992412607     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2016.06.002     Document Type: Review

References (89)

1. [1] Spitalnik, SL, Triulzi, D, Devine, DV, Dzik, WH, Eder, AF, et al. 2015 Proceedings of the National Heart, Lung, and Blood Institute's State of the Science in Transfusion Medicine symposium. Transfusion 55 (2015), 2282–2290.
2. [2] Hahn, T, McCarthy, PL Jr., Hassebroek, A, Bredeson, C, Gajewski, JL, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 31 (2013), 2437–2449.
3. [3] Brand, A, Doxiadis, IN, Roelen, DL, On the role of HLA antibodies in hematopoietic stem cell transplantation. Tissue Antigens 81 (2013), 1–11.
4. [4] Ciurea, SO, Thall, PF, Milton, DR, Barnes, TH, Kongtim, P, et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21 (2015), 1392–1398.
5. [5] Cutler, C, Kim, HT, Sun, L, Sese, D, Glotzbecker, B, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 118 (2011), 6691–6697.
6. [6] Fernandez-Vina, MA, de Lima, M, Ciurea, SO, Humoral HLA sensitization matters in CBT outcome. Blood 118 (2011), 6482–6484.
7. [7] Ruggeri, A, Rocha, V, Masson, E, Labopin, M, Cunha, R, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Societe Francophone d'Histocompatibilite et d'Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis. Haematologica 98 (2013), 1154–1160.
8. [8] Spellman, S, Bray, R, Rosen-Bronson, S, Haagenson, M, Klein, J, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 115 (2010), 2704–2708.
9. [9] Yoshihara, S, Maruya, E, Taniguchi, K, Kaida, K, Kato, R, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 47 (2012), 508–515.
10. [10] Yoshihara, S, Taniguchi, K, Ogawa, H, Saji, H, The role of HLA antibodies in allogeneic SCT: is the ‘type-and-screen’ strategy necessary not only for blood type but also for HLA?. Bone Marrow Transplant 47 (2012), 1499–1506.
11. [11] Chang, YJ, Zhao, XY, Xu, LP, Zhang, XH, Wang, Y, et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol, 8, 2015, 84.
12. [12] Hogge, DE, McConnell, M, Jacobson, C, Sutherland, HJ, Benny, WB, et al. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients. Transfusion (Paris) 35 (1995), 645–652.
13. [13] Seftel, MD, Growe, GH, Petraszko, T, Benny, WB, Le, A, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 103 (2004), 333–339.
14. [14] Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med, 337, 1997, 1861–1869.
15. [15] Ciurea, SO, de Lima, M, Cano, P, Korbling, M, Giralt, S, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 88 (2009), 1019–1024.
16. [16] Leffell, MS, Jones, RJ, Gladstone, DE, Donor HLA-specific abs: to BMT or not to BMT?. Bone Marrow Transplant 50 (2015), 751–758.
17. [17] Rowley, SD, Donato, ML, Bhattacharyya, P, Red blood cell–incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant 46 (2011), 1167–1185.
18. [18] Daniel-Johnson, J, Schwartz, J, How do I approach ABO-incompatible hematopoietic progenitor cell transplantation?. Transfusion (Paris) 51 (2011), 1143–1149.
19. [19] Rowley, SD, Liang, PS, Ulz, L, Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components. Bone Marrow Transplant 26 (2000), 749–757.
20. [20] Patrick, K, Lau, W, Gassas, A, McDougall, E, Doyle, J, et al. Major ABO incompatible BMT in children: determining what residual volume of donor red cells can safely be infused following red cell depletion. Bone Marrow Transplant 50 (2015), 536–539.
21. [21] Bensinger, WI, Buckner, CD, Thomas, ED, Clift, RA, ABO-incompatible marrow transplants. Transplantation 33 (1982), 427–429.
22. [22] Blacklock, HA, Gilmore, MJ, Prentice, HG, Hazlehurst, GR, Evans, JP, et al. ABO-incompatible bone-marrow transplantation: removal of red blood cells from donor marrow avoiding recipient antibody depletion. Lancet 2 (1982), 1061–1064.
23. [23] Gale, RP, Feig, S, Ho, W, Falk, P, Rippee, C, et al. ABO blood group system and bone marrow transplantation. Blood 50 (1977), 185–194.
24. [24] Stussi, G, Halter, J, Schanz, U, Seebach, JD, ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation. Transfus Apher Sci 35 (2006), 59–69.
25. [25] Gajewski, JL, Johnson, VV, Sandler, SG, Sayegh, A, Klumpp, TR, A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 112 (2008), 3036–3047.
26. [26] Cunard, R, Marquez, II, Ball, ED, Nelson, CL, Corringham, S, et al. Prophylactic red blood cell exchange for ABO-mismatched hematopoietic progenitor cell transplants. Transfusion (Paris) 54 (2014), 1857–1863.
27. [27] Lee, HJ, Gulbis, A, De Padua Silva, L, Hosing, C, Khouri, I, et al. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant 42 (2008), 67–69.
28. [28] Worel, N, Greinix, HT, Keil, F, Mitterbauer, M, Lechner, K, et al. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion (Paris) 42 (2002), 1293–1301.
29. [29] Kanda, J, Ichinohe, T, Matsuo, K, Benjamin, RJ, Klumpp, TR, et al. Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. Transfusion 49 (2009), 624–635.
30. [30] Worel, N, Kalhs, P, Keil, F, Prinz, E, Moser, K, et al. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion 43 (2003), 1153–1161.
31. [31] Stussi, G, Seebach, L, Muntwyler, J, Schanz, U, Gmur, J, et al. Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience. Br J Haematol 113 (2001), 251–253.
32. [32] Erker, CG, Steins, MB, Fischer, RJ, Kienast, J, Berdel, WE, et al. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. Transfusion 45 (2005), 1382–1390.
33. [33] Kim, JG, Sohn, SK, Kim, DH, Baek, JH, Lee, KB, et al. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 35 (2005), 489–495.
34. [34] Zaimoku, Y, Takami, A, Sato, H, Utsumi, M, Nakao, S, IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Int J Hematol 98 (2013), 96–101.
35. [35] Atay, D, Erbey, F, Akcay, A, Ozturk, G, Is ABO mismatch another risk factor for allogeneic hematopoietic stem cell transplantation in pediatric thalassemic patients?. Pediatr Transplant 19 (2015), 645–651.
36. [36] Lapierre, V, Kuentz, M, Tiberghien, P, Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 25 (2000), 507–512.
37. [37] Zupanska, B, Zaucha, JM, Michalewska, B, Malinowska, A, Brojer, E, et al. Multiple red cell alloantibodies, including anti-Dib, after allogeneic ABO-matched peripheral blood progenitor cell transplantation. Transfusion 45 (2005), 16–20.
38. [38] Young, PP, Goodnough, LT, Westervelt, P, Diersio, JF, Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation. Bone Marrow Transplant 27 (2001), 1305–1310.
39. [39] Leo, A, Mytilineos, J, Voso, MT, Weber-Nordt, R, Liebisch, P, et al. Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jk(a) after allogeneic PBPC transplantation. Transfusion 40 (2000), 632–636.
40. [40] Ting, A, Pun, A, Dodds, AJ, Atkinson, K, Biggs, JC, Red cell alloantibodies produced after bone marrow transplantation. Transfusion 27 (1987), 145–147.
41. [41] Abou-Elella, AA, Camarillo, TA, Allen, MB, Barclay, S, Pierce, JA, et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 35 (1995), 931–935.
42. [42] de La Rubia, J, Arriaga, F, Andreu, R, Sanz, G, Jimenez, C, et al. Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?. Transfusion 41 (2001), 106–110.
43. [43] Khalil, A, Zaidman, I, Elhasid, R, Peretz-Nahum, M, Futerman, B, et al. Factors influencing outcome and incidence of late complications in children who underwent allogeneic hematopoietic stem cell transplantation for hemoglobinopathy. Pediatr Hematol Oncol 29 (2012), 694–703.
44. [44] Sorror, ML, How I assess comorbidities before hematopoietic cell transplantation. Blood 121 (2013), 2854–2863.
45. [45] Hamidieh, AA, Moeininia, F, Tayebi, S, Shamshiri, AR, Behfar, M, et al. Efficacy of hepatic T2* MRI values and serum ferritin concentration in predicting thalassemia major classification for hematopoietic stem cell transplantation. Pediatr Transplant 19 (2015), 301–306.
46. [46] Kumar, A, Mhaskar, R, Grossman, BJ, Kaufman, RM, Tobian, AA, et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion 55 (2015), 1116–1127 [quiz 1115].
47. [47] Bercovitz, RS, Quinones, RR, A survey of transfusion practices in pediatric hematopoietic stem cell transplant patients. J Pediatr Hematol Oncol 35 (2013), e60–e63.
48. [48] Walters, M, Patience, M, Leisenring, W, Eckman, J, Scott, J, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 335 (1996), 369–376.
49. [49] Luban, NL, McBride, E, Ford, JC, Gupta, S, Transfusion medicine problems and solutions for the pediatric hematologist/oncologist. Pediatr Blood Cancer 58 (2012), 1106–1111.
50. [50] Sacher, RA, Kickler, TS, Schiffer, CA, Sherman, LA, Bracey, AW, et al. Management of patients refractory to platelet transfusion. Arch Pathol Lab Med 127 (2003), 409–414.
51. [51] Delaflor-Weiss, E, Mintz, PD, The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 14 (2000), 180–196.
52. [52] Slichter, SJ, Evidence-based platelet transfusion guidelines. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2007, 172–178.
53. [53] Figueiredo, C, Blaszczyk, R, Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34 + progenitor cells. J Stem Cells 9 (2014), 149–161.
54. [54] Figueiredo, C, Goudeva, L, Horn, PA, Eiz-Vesper, B, Blasczyk, R, et al. Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion (Paris) 50 (2010), 1690–1701.
55. [55] Gras, C, Schulze, K, Goudeva, L, Guzman, CA, Blasczyk, R, et al. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. Hum Gene Ther 24 (2013), 1018–1028.
56. [56] Drawz, SM, Marschner, S, Yanez, M, Garcia de Coca, A, Feys, HB, et al. Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions. Transfusion (Paris) 55 (2015), 1745–1751.
57. [57] Tobian, AA, Fuller, AK, Uglik, K, Tisch, DJ, Borge, PD, et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion (Paris) 54 (2014), 1523–1529 [quiz 1522].
58. [58] Pihusch, M, Bacigalupo, A, Szer, J, von Depka Prondzinski, M, Gaspar-Blaudschun, B, et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 3 (2005), 1935–1944.
59. [59] Atas, E, Kesik, V, Gursel, O, Treatment of massive gastrointestinal bleeding occurred during autologous stem cell transplantation with recombinant activated factor VII and octreotide. J Cancer Res Ther, 11, 2015, 667.
60. [60] Tang, Y, Wu, Q, Wu, X, Qiu, H, Sun, A, et al. Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia. Pak J Med Sci 31 (2015), 1389–1393.
61. [61] Yadav, SP, Sachdeva, A, Bhat, S, Katewa, S, Successful control of massive gastrointestinal bleeding following umbilical cord blood transplantation (UCBT) by use of recombinant activated factor VII (rFVIIa) and octreotide infusion. Pediatr Hematol Oncol 27 (2010), 24–30.
62. [62] Ballen, KK, Becker, PS, Yeap, BY, Matthews, B, Henry, DH, et al. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 22 (2004), 4087–4094.
63. [63] Ford, PA, Grant, SJ, Mick, R, Keck, G, Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. J Clin Oncol 33 (2015), 1674–1679.
64. [64] Booth, GS, Gehrie, EA, Bolan, CD, Savani, BN, Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant 19 (2013), 1152–1158.
65. [65] Worel, N, Panzer, S, Reesink, HW, Linkesch, W, Dickmeiss, E, et al. Transfusion policy in ABO-incompatible allogeneic stem cell transplantation. Vox Sang 98 (2010), 455–467.
66. [66] McPherson, ME, Anderson, AR, Haight, AE, Jessup, P, Castillejo, MI, et al. Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor. Transfusion (Paris) 49 (2009), 1977–1986.
67. [67] Ahmed, I, Teruya, J, Murray-Krezan, C, Krance, R, The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post-second hematopoietic stem cell transplant. Pediatr Transplant 19 (2015), 391–398.
68. [68] Park, JA, Lee, HH, Kwon, HS, Baik, CR, Song, SA, et al. Sirolimus for refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review of the treatment of post-transplant autoimmune hemolytic anemia. Transfus Med Rev 30 (2016), 6–14.
69. [69] Bride, KL, Vincent, T, Smith-Whitley, K, Lambert, MP, Bleesing, JJ, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood 127 (2016), 17–28.
70. [70] Khan, F, Linden, MA, Zantek, ND, Vercellotti, GM, Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation. Transfus Med 24 (2014), 187–188.
71. [71] Acs, G, Acs, P, Beckwith, SM, Pitts, RL, Clements, E, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61 (2001), 3561–3565.
72. [72] Yasuda, Y, Fujita, Y, Matsuo, T, Koinuma, S, Hara, S, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24 (2003), 1021–1029.
73. [73] Hedley, BD, Allan, AL, Xenocostas, A, The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 17 (2011), 6373–6380.
74. [74] Todaro, M, Turdo, A, Bartucci, M, Iovino, F, Dattilo, R, et al. Erythropoietin activates cell survival pathways in breast cancer stem–like cells to protect them from chemotherapy. Cancer Res 73 (2013), 6393–6400.
75. [75] Beguin, Y, Maertens, J, De Prijck, B, Schots, R, Seidel, L, et al. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. Am J Hematol 88 (2013), 990–996.
76. [76] Jaspers, A, Baron, F, Maertens, J, De Prijck, B, Schots, R, et al. Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation. Am J Hematol 90 (2015), E133–E134.
77. [77] Bussel, JB, de Miguel, PG, Despotovic, JM, Grainger, JD, Sevilla, J, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2 (2015), e315–e325.
78. [78] Tanaka, T, Inamoto, Y, Yamashita, T, Fuji, S, Okinaka, K, et al. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 2016.
79. [79] Ghavamzadeh, A, Mirzania, M, Kamalian, N, Sedighi, N, Azimi, P, Hepatic iron overload and fibrosis in patients with beta thalassemia major after hematopoietic stem cell transplantation: a pilot study. Int J Hematol Oncol Stem Cell Res 9 (2015), 55–59.
80. [80] Hamidieh, AA, Tayebi, S, Moeininia, F, Shamshiri, AR, Behfar, M, et al. T2(*) MRI changes in the heart and liver of ex-thalassemic patients after hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther 7 (2014), 103–108.
81. [81] Vitrano, A, Calvaruso, G, Tese, L, Gioia, F, Cassara, F, et al. Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET. Eur J Haematol, 2016, 10.1111/ejh.12740.
82. [82] Jodele, S, Davies, SM, Lane, A, Khoury, J, Dandoy, C, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 124 (2014), 645–653.
83. [83] Changsirikulchai, S, Myerson, D, Guthrie, KA, McDonald, GB, Alpers, CE, et al. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol 4 (2009), 345–353.
84. [84] Kennedy, GA, Kearey, N, Bleakley, S, Butler, J, Mudie, K, et al. Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant 45 (2010), 699–704.
85. [85] Labrador, J, Lopez-Corral, L, Lopez-Godino, O, Vazquez, L, Cabrero-Calvo, M, et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplant 49 (2014), 684–690.
86. [86] Laskin, BL, Goebel, J, Davies, SM, Khoury, JC, Bleesing, JJ, et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant 46 (2011), 682–689.
87. [87] de Fontbrune, FS, Galambrun, C, Sirvent, A, Huynh, A, Faguer, S, et al. Use of eculizumab in patients with allogeneic stem cell transplant–associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 99 (2015), 1953–1959.
88. [88] Jodele, S, Fukuda, T, Vinks, A, Mizuno, K, Laskin, BL, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation–associated thrombotic microangiopathy. Biol Blood Marrow Transplant 20 (2014), 518–525.
89. [89] Jodele, S, Fukuda, T, Mizuno, K, Vinks, AA, Laskin, BL, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 22 (2016), 307–315.